我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Novel siRNA therapy divesiran demonstrates positive safety profile in SANRECO trial, with 84% of treatment-emergent adverse effects being grade 1 and no serious adverse events reported. - The drug significantly reduced phlebotomy requirements from 79 pre-treatment procedures to only 7 during treatment and follow-up periods across all patients. - Divesiran successfully increased hepcidin levels and decreased hematocrit in all patient cohorts, showing potential as a new therapeutic option for polycythemia vera management.
